Active Cutaneous Anaphylaxis (ACA) in the Mouse Ear

Naoki Inagaki, Toru Miura, Hiroichi Nagai and Akihide Koda

Department of Pharmacology, Gifu Pharmaceutical University, Gifu 502, Japan

Received January 14, 1992 Accepted March 13, 1992

ABSTRACT—Active cutaneous anaphylaxis (ACA) was studied in the ear of female BALB/c mice. Mice were immunized with ovalbumin in the presence of aluminium hydroxide gel or complete Freund’s adjuvant (CFA). Two weeks after the immunization, ACA was elicited in the mouse ear by injecting 10 μl of antigen solution intradermally into the ear lobe. ACA was assessed by the amount of extravasated dye, which was given intravenously just after the antigen injection. Antiallergic drugs (tralilast, ketotifen and azelastine), antihistamines (chlorpheniramine, diphenhydramine and mequitazine), β-stimulants (isoproterenol and salbutamol), theophylline and glucocorticoids (hydrocortisone, prednisolone and dexamethasone) inhibited the reaction significantly. These drugs inhibited both ACA in mice immunized with alum-precipitated antigen and ACA in mice injected with CFA-emulsified antigen similarly. ACA in the mouse ear might be a useful tool for studying drugs for allergy.

Keywords: Active cutaneous anaphylaxis, Ear (mouse), Antiallergic drug, IgE antibody, IgG1 antibody

MATERIALS AND METHODS

Mice

Female BALB/c mice were used for ACA and male ddY mice were used for titration of serum antibodies. Both mice were purchased from Japan SLC, Inc. (Hamamatsu, Japan).

Antigen and adjuvants

Ovalbumin (OA, 5 times crystallized) was purchased from Seikagaku Kogyo Co., Ltd. (Tokyo, Japan). As adjuvants, aluminium hydroxide gel (alum) and complete Freund’s adjuvant (CFA) were used. Alum was prepared according to the method of Levine and Vaz (24), and CFA was obtained from Nacalai Tesque, Inc. (Kyoto, Japan).

ACA

Ten-weeks-old female BALB/c mice were immunized with OA in the presence of an adjuvant. To induce IgE antibody mainly, 1 μg of OA mixed with 1 mg of alum was injected intraperitoneally. To induce IgG1 antibody mainly, 100 μg of OA emulsified in CFA was given intraperitoneally. Four or five weeks later, in some experiments, booster immunization was performed in the same manner. Two weeks after the first immunization or 1 week after the booster immunization, ACA was
elicited in the ear of mice by injecting 10 μl of antigen saline solution followed by an intravenous injection of 0.25 ml of 0.5% Evans blue saline solution. Thirty minutes after the challenge, mice were sacrificed by cervical dislocation, and ears were removed for measurement of extravasated dye. To measure the amount of dye detected non-specifically, non-immunized mice received a similar antigenic challenge.

Extraction and quantification of extravasated dye was performed using a previously described method (15). Briefly, a pair of ears from a mouse were dissolved with 0.7 ml of 1 N KOH solution in a stoppered tube at 37°C overnight, and 9.3 ml of a mixture of 0.6 N phosphoric acid and acetone (5:13) was added. After vigorous shaking, precipitates were filtered off and the amount of dye was measured colorimetrically at 620 nm.

Mediator skin reaction

The mediator skin reaction was examined in immunized BALB/c mice as previously described (17). One week after the booster immunization, the skin reaction was elicited by injecting 10 μl of mediator solution into the ear. The reaction was evaluated similarly to ACA by assessing the amount of extravasated dye which was given intravenously just after the mediator injection. As mediators, 2 × 10^-4 g/ml histamine (hydrochloride, Nacalai Tesque), 2 × 10^-6 g/ml serotonin (creatininsulfate, Merck), 2 × 10^-6 g/ml platelet activating factor (PAF, Bachem), and 5 × 10^-8 g/ml leukotriene C4 (LTC4, Wako) were used.

Serum antibody titer

Serum IgE and IgG1 antibody titers were examined by means of ear PCA in male ddY mice (15). Serum samples were obtained from BALB/c mice one day before ACA and pooled within a group. Sera were two-fold serially diluted with saline and injected in a volume of 10 μl into ddY mouse ear. When assaying IgG1 antibody titer, sample sera were heated at 56°C for 2 hours before dilution (19, 25). For detecting IgG1 antibody, mice were challenged by intravenous injection of 0.25 ml of 0.5% Evans blue saline solution containing 0.25 mg of antigen 1.5 hours after the sensitization. For detecting IgE antibody, similar antigenic challenge was performed 48 hours after the sensitization. Thirty minutes later, mice were sacrificed by cervical dislocation, and the bluing reaction in the ear was evaluated.

Drugs

Tranilast (Kissei), ketotifen (fumarate, Sandoz), azelastine (hydrochloride, Eizai), chlorpheniramine (maleate, Sigma), diphenhydramine (hydrochloride, Sigma), mequitazine (Nicpon Shoji), isoprotenerol (hydrochloride, Sigma), salbutamol (sulfate, Fujikawa), theophylline (Sigma), hydrocortisone (acetate, aqueous suspension, Nippon Merck-Banyu), prednisolone (acetate, aqueous suspension, Shionogi) and dexamethasone (acetate, aqueous suspension, Banyu) were used. Tranilast, mequitazine, and theophylline were suspended in 0.2% sodium carboxymethyl cellulose solution, and aqueous suspensions of glucocorticoids were diluted with 0.2% sodium carboxymethyl cellulose saline solution. The others were dissolved in water. Drugs except for glucocorticoids, which were administered intraperitoneally 8 hours prior to ACA (22), were given to mice orally one hour prior to ACA. When drugs were given orally, mice were fasted for 6 hours before administration.

Statistics

Statistical analyses were performed by Student’s t-test.

RESULTS

Challenging antigen dose

Mice were immunized 2 times with OA in the presence of alum. One week after the booster immunization, ACA was elicited by injecting 0.01, 0.1 and 1 μg of the antigen into the ear. As shown in Fig. 1, 0.01–1 μg of the antigen caused potent reactions in a dose-dependent manner, and the amount of extravasated dye was 20.5–43.6 μg. When assessing the extravasated dye in the mouse ear, it is important for an accurate determination that the bluing reaction is limited within the ear lobe. We, therefore, chose a moderate dose of 0.1 μg for ACA elicitation and used this dose hereafter.

Relationships between ACA and serum antibody titers

Mice were immunized with OA in the presence of alum or CFA, and ACA was elicited with 0.1 μg of the antigen 2 weeks after the primary immunization and 1 week after the booster immunization. Serum samples were collected 1 day before ACA, and antibody titers were estimated by means of mouse ear PCA. Results are shown in Fig. 2. Two weeks after the primary immunization, IgG1 and IgE titers in the alum group were 1:2^6 and 1:2^9, respectively, and in the CFA group 1:2^9 and 1:2^4, respectively. In both groups, however, potent ACA with a similar intensity was elicited. One week after the booster immunization, antibody titers were elevated significantly as compared to those observed in the primary response, and the differences among antibody titers in the primary response disappeared. Although potent ACA was elicited in both the alum and CFA...
Fig. 1. Relationship between ACA and antigen dose. Mice were immunized with OA in the presence of alum 2 times at an interval of 4 weeks. ACA was elicited 1 week after the secondary immunization by injecting 0.01–1 μg of OA into the ear. Each value represents the mean and the standard error of 5 mice.

Fig. 2. Relationships between ACA and serum antibody titers. Mice were immunized with OA 2 times at an interval of 5 weeks. ACA was elicited 2 weeks after the primary immunization [A] and 1 week after the secondary immunization [B] by injecting 0.1 μg of OA into the ear. Serum samples were obtained 1 day before ACA. Results of ACA are the mean value and the standard error of 9 or 10 mice, except for the non-immunized groups of 3 mice. PCA titers were estimated using pooled sera. ND: not detected.
groups, the reaction was not as potent as that observed after the primary immunization. Based on these results, we decided to examine the effects of drugs on ACA elicited 2 weeks after the primary immunization.

**Effect of immunization on sensitivity of mouse ear against chemical mediators**

Effect of immunization on mediator skin reaction in the mouse ear was examined. Mice were immunized 2 times with OA in the presence of alum or CFA, and skin reactions by histamine, serotonin, PAF and LTC\(_4\) were elicited 1 week after the booster immunization. As shown in Fig. 3, although all mediators caused a significant vascular permeability increase, no significant difference was observed among non-immunized, alum and CFA groups.

**Effects of drugs on ACA**

Effects of antiallergic drugs on ACA in mice immunized with OA in the presence of alum or CFA were examined. Drugs were administered orally 1 hour prior to challenge. Results are shown in Fig. 4. Fasting for 6 hours resulted in depressed ACA in the control groups in comparison to those indicated in Fig. 2. Tranilast at doses of 100 and 200 mg/kg and ketotifen and azelastine at doses of 0.5 and 1 mg/kg significantly inhibited both ACA dose-dependently.

Results of antihistamines are shown in Fig. 5. Drugs were administered orally 1 hour prior to challenge. Chlorpheniramine at doses of 50 and 100 mg/kg, diphenhydramine at doses of 20 and 50 mg/kg, and mequitazine at doses of 2 and 5 mg/kg significantly inhibited both ACA dose-dependently.

Results of \(\beta\)-stimulants and theophylline are shown in Fig. 6. Drugs were administered orally 1 hour prior to challenge. Salbutamol at doses of 10 and 20 mg/kg and theophylline at doses of 50 and 100 mg/kg significantly inhibited both ACA dose-dependently. Although isoproterenol at the dose of 20 mg/kg significantly inhibited ACA in mice immunized in the presence of alum, it failed to inhibit ACA in mice immunized in the presence of CFA. In a separate experiment, however, it was confirmed that isoproterenol inhibited both ACA, and that the potency was slightly less than that of salbu-
tamol under the present experimental conditions (data not shown).

Results of glucocorticoids are shown in Fig. 7. Drugs were administered intraperitoneally 8 hours prior to challenge. Hydrocortisone at doses of 10 and 20 mg/kg and dexamethasone at doses of 0.5 and 1 mg/kg significantly inhibited both ACA dose-dependently. Although prednisolone in doses of 2 and 5 mg/kg inhibited ACA in mice immunized with CFA-emulsified antigen, it only showed a tendency to inhibit the ACA in mice immunized with alum-precipitated antigen.

**Discussion**

In the present study, we established a method for ear ACA in female BALB/c mice and demonstrated that several drugs for allergic diseases effectively inhibited the ACA. It is noteworthy that the ACA was highly reproducible in comparison with the mouse ear PCA reported previously (15), in spite of the active immunization.

Mice were immunized with an antigen, OA, in the presence of an adjuvant, alum or CFA. We used alum to induce IgE antibody effectively and CFA to induce IgG1 antibody predominantly (24, 26). Two weeks after
the primary immunization, potent and comparable ACA was observed in both groups of mice. Although both the IgE antibody titer in the alum group and the IgG1 antibody titer in the CFA group were high, 1:29, IgG1 antibody in the alum group and the IgE antibody in the CFA group were also detected, and their titers were not negligible. We considered, therefore, that both types of antibodies could be responsible for eliciting the ACA in both alum and CFA groups. One week after the secondary immunization, antibody titers were elevated significantly, and both IgE and IgG1 antibody titers in the alum group were 1:211, and those in the CFA group were 1:29 and 1:211, respectively. In spite of the elevated serum antibody titers, the ACA was not so potent as that observed 2 weeks after the primary immunization. These results suggest that the occurrence of ACA does not parallel the elevation in IgE or IgG1 antibody titer. On the other hand, as increased reactivity against various stimuli was observed in allergic patients (27, 28), we examined the effect of immunization on the mediator skin reaction in the mouse ear 1 week after the secondary immunization. No significant difference was observed among non-immunized, alum and CFA groups in skin reactions caused by histamine, serotonin, PAF and LTC4, suggesting that the immunizing procedure employed here does not alter the reactivity in mice against chemical mediators. Repeated challenge with antigen at a shorter interval may be effective for causing increased reactivity.

Antiallergic drugs, tranilast, ketotifen and azelastine, inhibited the ACA significantly. Inhibition of mediator release from mast cells may be involved in the inhibition of ACA by tranilast (4, 29), and the antihistaminic properties of ketotifen and azelastine may play important roles in their inhibition (5, 6). Antihistamines, chlorpheniramine, diphenhydramine and mequitazine also inhibited the ACA significantly. Mequitazine is a potent antihistamine with an antiasthma property (30, 31). Bronchodilating drugs, isoproterenol, salbutamol and theophylline, and glucocorticoids, hydrocortisone, prednisolone and dexamethasone, inhibited the ACA significantly. Although these drugs are reported to inhibit antigen-induced mediator release from mast cells (32–34), they also inhibit vascular permeability increase non-specifically (35, 36). These drugs inhibit PCA and skin reactions caused by chemical mediators significantly in rats and mice (22, 37). In rats, PCA is inhibited more potently than the mediator skin reaction by these drugs (37). On the contrary, in mice, glucocorticoids only inhibit PCA to an extent similar to inhibition of the mediator skin reaction (22). These results suggest that the inhibition of both mediator release from mast cells and vascular permeability increase by chemical mediators is involved in the inhibition of PCA in rats, and that the inhibition of vascular permeability increase is important in the case of mouse PCA. It is also suggested that inhibition of vascular permeability increase may play important roles in the inhibition of ACA by β-stimulants, theophylline and glucocorticoids observed in the present study. All drugs studied here inhibited the ACA in mice immunized with alum-precipitated antigen and CFA-emulsified antigen similarly. This may be related to the fact that both immunizing procedures resulted in the production of both IgE and IgG1 antibodies responsible for ACA. We reported previously, however, that mouse ear PCA
mediated by both IgE and IgG1 antibodies are inhibited similarly by these drugs (16, 20).

PCA is a reaction that involves mast cell activation and a subsequent increase in vascular permeability. Since a process of lymphocyte-antigen interaction leading to antibody production is also involved in ACA, drugs affecting antibody production should also be evaluated as antiallergic drugs. Mice are handled easily because of their small size and many interesting strains of mice are reported (9–12). Mice are the best experimental animals for inducing IgE antibody production. Furthermore, the ACA reported here is highly reproducible. Mouse ear ACA may become a useful tool for studying drugs for allergy.

Acknowledgment

This study was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan.

REFERENCES

1. Ovary, Z.: Passive cutaneous anaphylaxis in the mouse. J. Immunol. 81, 355–357 (1958)
2. Ovary, Z.: Immediate reactions in the skin of experimental animals provoked by antibody-antigen interaction. Prog. Allergy 5, 459–508 (1958)
3. Cox, J.S.G.: Disodium cromoglycate (FPL 670) ('Intal'): a specific inhibitor of reaginic antibody-antigen mechanisms. Nature 216, 1328–1329 (1967)
4. Koda, A., Nagai, H., Watanabe, S., Yanagihara, Y. and Sakamoto, K.: Inhibition of hypersensitivity reactions by a new drug, N(3',4'-dimethoxy-cinnamoyl) anthranilic acid (N-S5). J. Allergy Clin. Immunol. 57, 396–407 (1976)
5. Martin, U. and Romer, D.: The pharmacological properties of a new, orally active antianaphylactic compound: ketotifen, a benzocycloheptathiophene. Arzneimittelforschung 28, 770–782 (1978)
6. Katayama, S., Akimoto, N., Shionoya, H., Morimoto, T. and Katoh, Y.: Anti-allergic effect of azelastine hydrochloride on immediate type hypersensitivity reactions in vivo and in vitro. Arzneimittelforschung 31, 1196–1203 (1981)
7. Harada, M., Takeuchi, M., Fukao, T. and Katagiri, K.: A simple method for the quantitative extraction of dye extravasated into the skin. J. Pharm. Pharmacol. 23, 218–219 (1971)
8. Katayama, S., Shionoya, H. and Ohtake, S.: A new method for extraction of extravasated dye in the skin and the influence of fasting stress on passive cutaneous anaphylaxis in guinea pigs and rats. Microbiol. Immunol. 22, 89–101 (1978)
9. Ruitenbeek, E.J. and Elgersma, A.: Absence of intestinal mast cell response in congenitally athymic mice during Trichinella spiralis infection. Nature 264, 248–260 (1976)
10. Kitamura, Y., Shimada, M., Hatanaka, K. and Miyano, Y.: Development of mast cells from grafted bone marrow cells in irradiated mice. Nature 268, 442–443 (1977)
11. Kitamura, Y., Go, S. and Hatanaka, K.: Decrease of mast cells in W/W' mice and their increase by bone marrow transplantation. Blood 52, 447–452 (1978)
12. Kitamura, Y. and Go, S.: Decreased production of mast cells in SI/SI5 anemic mice. Blood 53, 492–497 (1979)
13. Feinberg, J.G.: Pinna al anaphylaxis: an additional anaphylactic site. Nature 191, 712 (1961)
14. Prouvost-Danon, A. and Binaghi, R.: Reaginic antibody in adult and young mice. Production and biological properties. Int. Arch. Allergy 38, 648–656 (1970)
15. Inagaki, N., Goto, S., Nagai, H. and Koda, A.: Mouse ear PCA as a model for evaluating antianaphylactic agents. Int. Arch. Allergy Appl. Immunol. 74, 91–92 (1984)
16. Inagaki, N., Goto, S., Nagai, H. and Koda, A.: Pharmacological characterization of mouse ear PCA. Int. Arch. Allergy Appl. Immunol. 78, 113–117 (1985)
17. Inagaki, N., Goto, S., Yamasaki, M., Nagai, H. and Koda, A.: Studies on vascular permeability increasing factors involved in 48-hour homologous PCA in the mouse ear. Int. Arch. Allergy Appl. Immunol. 80, 285–290 (1986)
18. Inagaki, N., Goto, S., Nagai, H. and Koda, A.: Homologous passive cutaneous anaphylaxis in various strains of mice. Int. Arch. Allergy Appl. Immunol. 81, 58–62 (1986)
19. Inagaki, N., Nagai, H., Nakatomi, I. and Koda, A.: Comparative study of 1.5-hour and 48-hour homologous passive cutaneous anaphylaxis in the mouse ear. J. Pharmacobiodyn. 11, 31–38 (1988)
20. Inagaki, N., Nagai, H., Xu, Q., Daikoku, M., Nakatomi, I. and Koda, A.: Effects of different drugs on passive cutaneous anaphylaxis elicited in the mouse ear at 1.5 hours. Int. Arch. Allergy Appl. Immunol. 86, 157–161 (1988)
21. Inagaki, N., Nagai, H. and Koda, A.: Comparative study of IgG1 and IgE antibody mediated homologous PCA in the mouse ear. Lack of cross-desensitization of IgG1 antibody mediated PCA to IgE antibody mediated PCA. Int. Arch. Allergy Appl. Immunol. 86, 325–330 (1988)
22. Inagaki, N., Miura, T., Nagai, H., Ono, Y. and Koda, A.: Inhibition of vascular permeability increase in mice. An additional anti-allergic mechanism of glucocorticoids. Int. Arch. Allergy Appl. Immunol. 87, 254–259 (1988)
23. Inagaki, N., Miura, T., Ohira, K., Nagai, H., Xu, Q. and Koda, A.: Effect of CV-3988, a specific antagonist against platelet activating factor, on homologous passive cutaneous anaphylaxis in the mouse ear. J. Pharmacobiodyn. 13, 272–277 (1990)
24. Levine, B.B. and Vaz, N.M.: Effect of combinations of inbred strain, antigen, and antigen dose on immune responsiveness and reagin production in the mouse. Int. Arch. Allergy Appl. Immunol. 87, 254–259 (1988)
25. Prouvost-Danon, A., Binaghi, R.A. and Abadie, A.: Effect of heating at 56°C on mouse IgE antibodies. Immunochim. 14, 81–84 (1977)
26. Tung, A.S., Chiorazzi, N. and Katz, D.H.: Regulation of IgE antibody production by serum molecules. I. Serum from complete Freund's adjuvant-immune donors suppresses irradiation-enhanced IgE production in low responder mouse strains. J. Immunol. 120, 2050–2059 (1978)
27. Boushey, H.A.: Asthma and bronchial hyperreactivity. Possible role of disturbance in autonomic regulation. Prog. Resp. Res. 19, 124–136 (1985)
28. Holtzman, M.J.: Inflammation of the airway epithelium and the development of airway hyperresponsiveness. Prog. Resp. Res. 19, 165–172 (1985)
29 Azuma, H., Banno, K. and Yoshimura, T.: Pharmacological properties of N-(3',4'-dimethoxycinnamoyl)anthranilic acid (N-5'), a new anti-atopic agent. Br. J. Pharmacol. 58, 483–488 (1976)

30 Kohno, S., Yamamura, H., Ohata, K., Nagai, H., Koda, A., Yanagihara, Y., Shida, T., Masuki, S., Yoshida, Y., Tatumi, H., Toriya, M., Tsujino, M., Mizuno, K. and Fujimura, H.: Antiallergic effects of mequitazine. 1. In vitro experiments. Folia Pharmacol. Japon. 92, 145–157 (1988) (Abs. in English)

31 Kohno, S., Yamamura, H., Ohata, K., Togawa, M., Nagai, H., Koda, A., Yanagihara, Y., Shida, T., Yatsuzuka, A., Yoshida, Y., Tatumi, H. and Fujimura, H.: Antiallergic effects of mequitazine. 2. In vivo experiments. Folia Pharmacol. Japon. 92, 159–165 (1988) (Abs. in English)

32 Marone, G., Ambrosio, G., Bonaduce, D., Genovese, A., Triggiani, M. and Condorelli, M.: Inhibition of IgE-mediated histamine release from human basophils and mast cells by fenoterol. Int. Arch. Allergy Appl. Immunol. 74, 356–361 (1984)

33 Foreman, J.C., Mongar, J.L., Gomperts, B.D. and Garland, L.G.: A possible role for cyclic AMP in the regulation of histamine secretion and the action of cromoglycate. Biochem. Pharmacol. 24, 538–540 (1975)

34 Daeron, M., Sterk, A.R., Hirata, F. and Ishizaka, T.: Biochemical analysis of glucocorticoid-induced inhibition of IgE-mediated histamine release from mouse mast cells. J. Immunol. 129, 1212–1218 (1982)

35 Green, K.L.: The anti-inflammatory effect of catecholamines in the peritoneal cavity and hind paw of the mouse. Br. J. Pharmacol. 45, 322–332 (1972)

36 Svensjö, E. and Roempke, K.: Time-dependent inhibition of bradykinin- and histamine-induced microvascular permeability increase by local glucocorticoid treatment. Prog. Resp. Res. 19, 173–180 (1985)

37 Inagaki, N., Miura, T., Daikoku, M., Nagai, H. and Koda, A.: Inhibitory effects of β-adrenergic stimulants on increased vascular permeability caused by passive cutaneous anaphylaxis, allergic mediators, and mediator releasers in rats. Pharmacology 39, 19–27 (1989)